USFDA completes inspection of Biocon's Telangana plant, finds no fault

A Biocon facility. Photo: Company's website

Biotechnology major Biocon Monday said the US health regulator has completed the inspection of its Telangana manufacturing facility without making any observations.

"The United States Food and Drug Administration (USFDA) conducted a good manufacturing practice (GMP) inspection of our active pharmaceutical ingredients (APIs) manufacturing facility at Telangana from December 12-14, 2018," Biocon said in a regulatory filing Monday

The inspection was concluded without any observations and no Form 483 was issued, the company added.

A Form 483, is issued by the USFDA to notify a company's management of any objectionable condition at its manufacturing facility. The form is issued after completing the inspection.

Shares of Biocon were trading 2.07 per cent lower at Rs 633 apiece on the BSE.



Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel